For UK MedTech companies
Your international clinical data is not enough for NHS buyers
NHS clinical decision-makers routinely reject evidence that doesn't reflect UK patient populations, care pathways, or healthcare economics. Without UK-specific data, adoption stalls regardless of how strong your global evidence is.
Two minutes. Solva follows up with specific UK clinical evidence options.
- Repeated rejections or prolonged evaluation cycles by NHS procurement teams and NICE
- Difficulty securing pilot sites or early adopters within NHS trusts
- Sales teams struggling to articulate product value without compelling UK data
- Competitors with UK evidence gaining significant market share
- Increased resource allocation to address evidence gaps and repeated submissions
- Diversion of R&D efforts from new product development to retrospective evidence generation
- Significant loss of potential revenue from delayed or denied NHS market access
- Increased operational costs associated with prolonged market entry efforts
- Delayed access for UK patients to potentially beneficial MedTech innovations
- Suboptimal patient outcomes if less effective, but locally evidenced, alternatives are adopted
- Perception as a company unable to meet local regulatory and evidence standards
- Damage to brand credibility within the UK healthcare ecosystem
While a precise '4x higher adoption rate' is not directly verifiable from official NICE publications, numerous NHS and NICE documents underscore the critical importance of UK-specific clinical evidence for successful MedTech adoption within the NHS, implying that international evidence alone is often insufficient and leads to significantly slower uptake. (NHS England, 2024; NICE, 2023)
Frequently asked questions
Why does this problem persist?
NHS clinical buyers are sceptical of international evidence that doesn't reflect UK patient populations, care pathways, or healthcare economics. Without UK clinical evidence, adoption is slow regardless of the international evidence base.
What is the cost of leaving it unaddressed?
MedTech products without sufficient UK clinical evidence often face significant delays in NHS adoption, potentially leading to substantial foregone revenue. The cost of generating robust UK clinical evidence, while considerable (e.g., clinical trials can range from hundreds of thousands to millions of pounds), is typically a fraction of the long-term revenue lost due to prolonged market access delays. (NIHR, 2025; ABPI, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.